| 2022-12-22 |
复牌提示：
2022-12-21 19:50:31 停牌，复牌日期 2022-12-23 00:00:01
|
| 2022-11-03 |
详情>>
股本变动：
变动后总股本4509.12万股
|
| 2022-11-03 |
详情>>
业绩披露：
2023年中报每股收益3.53美元,归母净利润1.61亿美元,同比去年增长428.09%
|
| 2022-11-01 |
财报披露：
美东时间 2022-11-01 盘前发布财报
|
| 2022-08-04 |
详情>>
业绩披露：
2023年一季报每股收益1.20美元,归母净利润5455.40万美元,同比去年增长305.67%
|
| 2022-06-28 |
股东大会：
将于2022-08-10召开股东大会
会议内容 ▼▲
- 1.Elect the three Class III director nominees listed in the accompanying proxy statement (the “Proxy Statement”) to serve for a three-year term until the 2025 Annual Meeting of Stockholders;
2.Consider a non-binding, advisory vote to approve the compensation of our named executive officers;
3.Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2023;
4.Consider and act upon any matter which may properly come before the 2022 Annual Meeting and any adjournments or postponements thereof.
|
| 2022-05-20 |
详情>>
业绩披露：
2022年年报每股收益3.00美元,归母净利润1.37亿美元,同比去年增长-39.47%
|
| 2022-05-20 |
详情>>
业绩披露：
2020年年报每股收益4.49美元,归母净利润2.03亿美元,同比去年增长-21.62%
|
| 2022-02-03 |
详情>>
业绩披露：
2022年三季报(累计)每股收益1.68美元,归母净利润7618.00万美元,同比去年增长-54.83%
|
| 2021-10-28 |
详情>>
业绩披露：
2022年中报每股收益0.67美元,归母净利润3042.80万美元,同比去年增长-71.51%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.59美元,归母净利润-2652.5万美元,同比去年增长-159.49%
|
| 2021-08-05 |
详情>>
业绩披露：
2021年一季报每股收益0.99美元,归母净利润4458.80万美元,同比去年增长-49.86%
|
| 2021-06-29 |
股东大会：
将于2021-08-11召开股东大会
会议内容 ▼▲
- 1.Elect the three Class II director nominees listed in the accompanying proxy statement (the “Proxy Statement”) to serve for a three-year term until the 2024 Annual Meeting of Stockholders;
2.Consider a non-binding, advisory vote to approve the compensation of our named executive officers;
3.Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2022;
4.Consider and act upon any matter which may properly come before the 2021 Annual Meeting and any adjournments or postponements thereof.
|
| 2021-05-21 |
详情>>
业绩披露：
2021年年报每股收益5.00美元,归母净利润2.26亿美元,同比去年增长11.09%
|
| 2021-02-04 |
详情>>
业绩披露：
2021年三季报(累计)每股收益3.74美元,归母净利润1.69亿美元,同比去年增长-1.48%
|
| 2020-11-06 |
详情>>
业绩披露：
2021年中报每股收益2.37美元,归母净利润1.07亿美元,同比去年增长4.71%
|
| 2020-06-30 |
股东大会：
将于2020-08-12召开股东大会
会议内容 ▼▲
- 1.Elect the three Class I director nominees listed in the accompanying proxy statement (the “Proxy Statement”) to serve for a three-year term until the 2023 Annual Meeting of Stockholders;
2.Consider a non-binding, advisory vote to approve the compensation of our named executive officers;
3.Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2021;
4.Consider and act upon any matter which may properly come before the 2020 Annual Meeting and any adjournments or postponements thereof
|
| 2019-06-25 |
股东大会：
将于2019-08-07召开股东大会
会议内容 ▼▲
- 1)Elect the two Class III director nominees listed in the accompanying proxy statement (the “Proxy Statement”) to serve for a three-year term until the 2022 Annual Meeting of Stockholders;
2)Consider a non-binding, advisory vote to approve the compensation of our named executive officers;
3)Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2020;
4)Consider and act upon any matter which may properly come before the 2019 Annual Meeting and any adjournments or postponements thereof.
|
| 2018-06-22 |
股东大会：
将于2018-08-08召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to our Board of Directors to serve for three-year terms extending until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To hold an advisory vote on executive compensation;
3.To amend and restate the ABIOMED, Inc. Amended and Restated 2015 Omnibus Incentive Plan, or the Amended and Restated 2015 Plan, and to increase the number of shares of common stock available for issuance thereunder by 1,725,000 shares to 4,985,000 shares;
4.To ratify the appointment of our independent registered public accounting firm for the fiscal year ending March 31, 2019;
5.To consider and act upon any other matter which may properly come before the Annual Meeting or any adjourned session thereof.
|
| 2017-06-23 |
股东大会：
将于2017-08-09召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to our Board of Directors to serve for three-year terms extending until the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To hold an advisory vote on executive compensation;
3.To hold an advisory vote on the frequency of future Stockholder advisory votes on executive compensation;
4.To ratify the appointment of our independent registered public accounting firm for the fiscal year ending March 31, 2018;
5.To consider and act upon any other matter which may properly come before the Annual Meeting or any adjourned session thereof.
|
| 2016-06-30 |
股东大会：
将于2016-08-10召开股东大会
会议内容 ▼▲
- 1. To elect two Class III directors to our Board of Directors to serve for three-year terms extending until the 2019 Annual Meeting of stockholders or until their successors are duly elected and qualified;
2. To hold an advisory vote on executive compensation;
3. To amend and restate the ABIOMED, Inc. 2015 Omnibus Incentive Plan (the “2015 Plan”) and to increase the number of shares of common stock available for issuance thereunder by 1,260,000 shares;
4. To ratify the appointment of our independent registered public accounting firm for the fiscal year ending March 31, 2017;
5. To consider and act upon any other matter which may properly come before the Annual Meeting or any adjourned session thereof.
|
| 2015-07-02 |
股东大会：
将于2015-08-12召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to the company's Board of Directors to serve for three year terms extending until the 2018 Annual Meeting of stockholders and their successors are duly elected and qualified;
2.To hold an advisory vote on executive compensation;
3.To approve the 2015 Omnibus Incentive Plan;
4.To ratify the appointment of the company's independent registered public accounting firm for the fiscal year ending March 31, 2016;
5.To consider and act upon any other matter which may properly come before the Annual Meeting or any adjourned session thereof.
|
| 2014-12-31 |
详情>>
内部人交易：
SUTTER MARTIN P股份增加427.00股
|
| 2014-07-10 |
股东大会：
将于2014-08-13召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon the election of two Class I directors;
2.To consider and vote upon a non-binding advisory “say on pay” proposal to approve the compensation of our named executive officers;
3.To consider and vote upon a proposal to approve amendments to our Second Amended and Restated 2008 Stock Incentive Plan, which include increasing by 1,700,000 shares the number of shares of common stock that we may issue under the Plan;
4.To consider and vote upon ratification of the appointment of our independent registered public accounting firm;
5.To consider and act upon any other matter which may properly come before the Annual Meeting or any adjourned session thereof.
|
| 2013-07-03 |
股东大会：
将于2013-08-14召开股东大会
会议内容 ▼▲
- 1. To consider and vote upon the election of three Class III directors;
2. To consider and vote upon a non-binding advisory “say on pay” proposal to approve the compensation of our named executive officers;
3. To consider and vote upon ratification of the appointment of our independent registered public accounting firm;
4. To consider and act upon any other matter which may properly come before the Annual Meeting or any adjourned session thereof.
|